Why tracking

genotype-specific HPV persistence matters

HPV infection history and current HPV results are both critical when assessing the risk for cervical cancer.1

Persistence of infections by high-risk HPV genotype is the single greatest risk factor for malignant progression.2

The BD Onclarity™ HPV Assay is the only FDA-approved assay that allows you to track persistent HPV infections using extended genotyping (detection of HPV types beyond HPV 16 and 18).3,4

Persistent genotype-specific HPV infection increase the risk of cervical disease2,5

Cumulative proportion of ≥CIN2 among women with genotype-specific HPV persistence*5

Adapted from Elfgren et al. Am J Obstet Gynecol. 2017;216:264.e1-7.
*12,527 women aged 32-38 years with follow up of 195 women attending colposcopy who were cytologically normal but persistently HPV positive for at least 1 year.

MONITORING GENOTYPE-SPECIFIC HPV PERSISTENCE IS KEY TO IDENTIFYING YOUR PATIENTS AT MOST RISK FOR DEVELOPING CERVICAL DISEASE.1,2,5

Extended genotyping helps track genotype-specific HPV persistence

HPV infection history and current HPV results are both critical when assessing the risk for cervical cancer and guiding patient management.1

THE BD ONCLARITY™ HPV ASSAY IS THE ONLY FDA-APPROVED ASSAY THAT HELPS TRACK GENOTYPE-SPECIFIC HPV PERSISTENCE USING EXTENDED GENOTYPING3,4

  • CIN, cervical intraepithelial neoplasia;
  • CIN2, cervical intraepithelial neoplasia grade 2;
  • FDA, Food and Drug Administration;
  • HPV, human papillomavirus;
  • hrHPV, high-risk human papillomavirus.
  1. 1. Perkins RB et al. J Low Genit Tract Dis. 2020;24:102-131.
  2. 2. Bodily J et al. Trends Microbiol. 2011;19(1):33-39.
  3. 3. BD Onclarity™ HPV Assay European Product information, 8089899(14). Updated November 2020.
  4. 4. BD Press Release. BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities. July 22, 2020.
  5. 5. Elfgren K et al. Am J Obstet Gynecol. 2017;216(3):264.e1-7.